These approvals will change the paradigm for treating cancer patients,” Narasimhan says. The medicine now approved for use ...

Novartis is proud to share that CEO Vas Narasimhan, M.D., has been named to the 2025 TIME100 Health list—recognizing 100 of the most influential people driving the future of global health.

The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that ...

May 8, 2025 – Today, TIME reveals the second annual TIME100 Health list recognizing the 100 most influential individuals in ...

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

Proxy advisor Ethos has called on Holcim shareholders to reject the company's remuneration proposals, saying Chairman Jan ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

The TIME100 Health list, assembled by the American news magazine TIME, highlights global leaders, advocates, and innovators ...

TIME magazine has named physician Tahmeed Ahmed, executive director of icddr,b, in 2025 TIME100 Health. Every year, TIME ...